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Abstract 
4-5% of neonates are affected by rare diseases, 75% of which occur in children under ten years of age. This fact requires 
additional costs and special access. The aim of this paper is to analyze expenditures, policy and rare disease health care 
legislation (children comprise most of the patients). The survey focuses on the EU countries in comparison to the situation in the 
Czech Republic. The basic methods used are literature review, the analysis of available statistics data regarding the number of 
persons and related financial requirements for the treatment of rare diseases. The time series and histograms are generated. 
Based on the analysis, it was discovered that there are no fundamental differences between the care of people with rare diseases 
in the EU and in the Czech Republic. Current legislation and activities at the EU level stimulate the member states (including the 
Czech Republic) to further support in this field. Suitable and appropriate conditions for the social integration of children suffering 
from rare diseases are created. Treatment of rare diseases involves significant financial costs associated not only with the drugs 
themselves, but also with the followed social integration. New methodologies and programs for this segment are formed in the 
EU and in the Czech Republic. These strategies set out a shared vision for improving the lives of all those with rare diseases. The 
focus throughout is patients and families. 
© 2015 The Authors. Published by Elsevier Ltd. 
Peer-review under responsibility of the Organising Committee of ICEEPSY 2014. 
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1. Introduction
RD’s are defined in the EU as affecting no more than 5 per 10,000 people. This low prevalence results into small
or very small numbers of patients who therefore feel particularly isolated. The isolation felt by RD patients is not 
only geographical but also means marginalization within society at large and within healthcare systems designed for 
common diseases (EUROPEAN COMMISSION, 2012). Rare Diseases are a complex mix of heterogeneous diseases, 
currently numbering 5,000 to 7,000 in total. Up to 2009, one or more responsible genes were identified for only 2105 
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of the over 6,000 rare diseases listed on the Orphanet website. For the vast majority of these diseases, no research is 
being conducted. There are only 395 patient registries across Europe and less than 150 rare diseases do have a 
marketed drug. Their heterogeneity means that research and therapeutic responses should be diverse and elaborated 
in each disease or group of RDs. In addition, for the same disease, symptoms can affect different organs or systems.  
This is largely a hereditary or congenital disease, which has very low incidence (prevalence) in the population. A 
rare disease is defined in the event when it affects less than 5 people in every 10,000. In conversion it is less than 1 
patient in 2,000. There are more than 8,000 rare diseases from which 80-90% are genetically determined. The main 
problem is that there are too many patients, but in the Czech Republic is a low number of specialised departments (in 
the future 10-20 departments are planned for development). The most common symptoms of these diseases are 
usually detected soon after birth, when 4-5% of newborns and infants are affected (e.g. some congenital defects, 
hereditary metabolic disorders, genetically determined diseases and rare cancers) (DOLEAL, T. & KLIME, 2013). 75% 
of rare diseases occur in children under ten years of age. A specific treatment is only possible for a small number of 
diseases. Because of this, approximately 1/3 of patients die before five years of age. Furthermore, they can also 
occur in childhood and adulthood. The neonatal screening is crucial for the diagnosis. In the Czech Republic there 
are 13 diseases examined and the introduction of screening significantly restricted the number of affected 
individuals.  
"The strategy of the EU in the field of rare diseases aims to unite the limited resources that are currently across 
the member countries. Specific measures include (EUROPEAN COMMISSION, 2012): 
V implementation of national plans for rare diseases in member states, whose aim is to ensure that patients   
with rare diseases have universal access to high quality care, including diagnostics, therapies and medicinal products 
for rare diseases (orphan drugs); 
V ensuring research of the causes and treatments for rare diseases; 
V       gathering expertise on rare diseases at European level; 
V       strengthening co-operation with patient organisations for rare diseases; 
V       ensuring the sustainability of activities in the field of rare diseases. 
All these areas are further developed at EU level within European legislation and incorporated into national health 
systems of different EU member states through national strategies. The National Strategy aims to initiate the process 
of creating functional and cost-effective systems for the treatment of rare diseases as well as the involvement of all 
stakeholders, including patients. This task has been implemented since 2011 also in the Czech Republic (EURORDIS , 
2012). 
The aim of this paper is to analyse the evolution of expenditure on rare diseases in recent years in EU countries, 
focusing on the Czech Republic, and answering the research question of whether a higher economic level of certain 
countries also has higher expenditure on orphan drugs. First, the basic economic characteristics such as GDP and the 
share of health expenditure to GDP in recent years will be compared. Subsequently, the attention will be focused on 
the actual cost of treatment of rare diseases. From the perspective of the needs of children with rare diseases, the 
requirements for integration of these children into the team will be specified. 
2. Methods 
The basic methods used are literature review, the analysis of available statistics data regarding the number of 
persons and related financial requirements for the treatment of rare diseases. The time series and histograms are 
generated. 
 
3. Healthcare spending in the European Union and the Czech Republic 
This paper aims to answer the research question of whether higher economic level is related to greater 
expenditures on the treatment of rare diseases. For this purpose, the evolution of GDP, healthcare expenditure and 
subsequently expenditure on treatment of rare diseases will be observed. So far there were fears that the cost of 
treatment of rare diseases will have a negative impact on the structure of healthcare expenditure, given their high 
level. On the other hand, as already mentioned above, the economies’ costs relate primarily to the treatment and 
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subsequent care of children up to ten years of age. Due to the general attitudes of the EU, in terms of efforts for 
improving living conditions and the promotion of mutual solidarity, the expenditure on research and treatment of 
rare diseases are supported.  
In terms of the development of one of the main macro-economic indicators – GDP, it can be said that the overall 
EU economic level is higher than in the Czech Republic. Moderate growth in recent years is typical for both 
comparator subjects (Figure 1). Within the EU, 18 Eurozone countries were selected, because for this group of 
countries there are indicators of healthcare expenditure available on the treatment of patients with rare diseases and 
later comparison is possible. 
 
   
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Gross Domestic Product at market prices (Purchasing Power Standard per inhabitant)*, own processing according to (EUROSTAT, 2014) 
Expenditure on healthcare make up 9-11% of GDP in the European Union, in the Czech Republic it is 6-8%. In 
both entities, there has been a slight increase since 1995 (Figure 2).  
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Health expenditure, total (% of GDP), own processing according to (WHO, 2014) 
From the point of both of these indicators, the Eurozone countries enjoy a better economic level. 
 
 
* The Eurozone, officially called the euro area, is an economic and monetary union (EMU) of 18 European Union 
(EU) member states that have adopted the euro (
) as their common currency and sole legal tender. 
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3.1. Expenditure for the treatment of rare diseases  
The annual cost of existing orphan drugs per patient ranged from 
1,251 to 
407,631 with a median per patient 
cost of 
32,242. The budget impact of orphan medicines in Europe has grown steadily over the 10 years (European 
Commission, 2012). The share of these expenditures in total expenditures on drugs in healthcare is shown in figure no., 
which also shows the expected expenditure up to 2020 (Figure 3). Expenditure for orphan drugs should stagnate 
around 5%.  
 
 
 
 
 
 
 
Fig. 3: The percentage of the cost of 
Orphan Drugs of total expenditure on drugs in 
the Eurozone, (Doleal, 2014) 
The situation in the Czech 
Republic for the period available for 
comparison, i.e. the years between 
2007 - 2012, corresponds almost 
identically to expenditures in the EU. In relation to the economic situation of the Czech Republic, it is a higher 
burden than in Eurozone countries (Figure 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: The percentage of the cost of Orphan Drugs in relation to total expenditure on drugs in the Czech Republic, own processing according to 
(Doleal, 2014) 
Over a thousand drugs in the research covers only 1% of illnesses and more than 75% of drugs are available in 
the Czech Republic. Currently all of the orphan drugs require additional payment (IHETA, 2012). In the Czech 
Republic it is approximately 600-800,000 patients. If we divide them according to the individual diseases, there 
would be hundreds of them, often dozens of patients, or even individuals within each diagnosis (LHOTÁKOVÁ & 
KUBÁKOVÁ, 2013). In comparison with the European Union, the cost in the Czech Republic is slightly lower. Costs 
in the EU in 2010 accounted for 3.3% and the estimate for 2016 is 4.6%. Furthermore, the cost should not rise 
before 2020 but should actually decrease slightly. Sweden and France are around 3%, more precisely Sweden 2.7% 
and France 3.2%. Compared to the study for the EU and the Czech Republic, these countries are predicted to have a 
steady increase in the budget.  
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3.2. The potential of the market for orphan drugs 
The development of orphan drugs may among other things mean a burden on the economic system. The present 
studies suggest that the development of these drugs brings higher profits than the development of other drugs 
(Figure 5). (DRUMMOND, 2008), (HUGHES-WILSON, 2012), (MEEKINGS, 2012), 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Growth rate of orphan versus non-orphan drugs 2001 – 2010, (THOMSON REUTERS, 2012) 
The compound annual growth rate (CAG R) of the orphan drug market between 2001 and 2010 was an 
impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs. This data, 
combined with the increasing number of orphan drug approvals, suggests that the CAG R of launched orphan drugs 
will outshine that of the non-orphan control drugs over the next 30 years (THOMSON REUTERS, 2012). 
4. Needs of pupils with rare diseases 
As has already been discovered, 75% of patients with rare diseases are children under 10 years of age. This fact is 
closely related to the issue of needs for students in the learning process. According to (MMT, 2002) the school that 
accepts a child with a rare disease, should meet certain minimum requirements. It's not just about the particulars of 
the administrative proceedings, architectural barriers and the possibility of providing special aids. It also concerns 
other aspects that affect the successful integration of a child with disabilities, such as the overall atmosphere of the 
school and the level (technical and human) of teaching staff members. The incorporation of these pupils is related to 
the creation of individual education plans and communication with their legal representatives.  
4.1. Factors accompanying the education of a child with rare diseases at school 
The adoption of a child with a rare disease into a normal class in a kindergarten, primary or secondary school, is 
still a more natural way of solving their educational needs.  
For teaching staff the knowledge (and interpretation) of the following findings have great importance, which we 
can observe in many cases in families caring for a child with a rare disease (MICHALÍK, J. et al., 2012): 
1. Concerns about the fate and health of a child, leading to greater caution. 
2. Distrust and increased sensitivity to institutions and their representatives. 
3. Strongly felt economic and social uncertainty. 
4. Greater dependence on counselling and assessment service institutions and their staff. 
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5. Increased mental and physical fatigue. 
6. Domestic support of the educational process. 
Good and work with the above mentioned factors ultimately determines the success of this method of education. 
Education of pupils with SEP compared to the main educational stream significantly economically challenging 
because it requires an individual approach to a pupil, which is also regarded by reduced number of pupils in a 
classroom, higher demands on teachers or special education requirements and often also costly special aids to 
teaching. The competent authority of the county or territorial unit will provide funding for a school for additional 
costs associated with teaching this pupil and security their training needs. Even so, the care cannot manage without 
increased financial demands on the legal representatives. 
5. Conclusion    
The aim of this paper was to analyse the relationship between economic level of the EU and the Czech Republic 
(characterised by the development of GDP and healthcare expenditures) and expenditure on orphan drugs. The 
comparison of the development of basic macro-economic variables shows that the EU as a body has almost identical 
expenditure on orphan drugs as the Czech Republic, and despite the fact that the EU has a consistently higher level 
of GDP as well as higher spending on healthcare. The assumption of higher spending on orphan drugs in the case of 
higher economic level of countries was therefore not confirmed. In the Czech Republic in recent years there has 
been a concern regarding rapid cost increases for these drugs. In terms of predictions for EU countries and the Czech 
Republic, we expect a stop in the increase of the costs. Conversely, in countries where these expenses are lower than 
the Eurozone’s average (Sweden 2.7% and France 3.2%) there is an expected increase. This also means that in the 
Czech Republic we do not need to worry about the rapid increase in costs because the limited number of existing 
orphan drugs in combination with small numbers of patients will not occur in the health system in the future by the 
way of a steep rise in the cost of treatment for rare diseases.  
Currently, there are National plans for rare diseases, which include aid for research and drug development, 
strengthening co-operation with patient organisations for rare diseases, plans for the inclusion of students in the 
educational process. The limiting factor in the National Plan of the Czech Republic is the fact that there has not been 
any budget allocated for its implementation by the government nor the Ministry of Health. To what extent 
performance will be ensured depends largely on the initiative of professional institutes and physicians, patient 
organisations mainly working on a voluntary basis and the willingness of officials to dedicate to this issue. 
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